Showing results (91-100 of 138) with videos related to
Sort By:
Pageof 14
Interdisciplinary Sciences, Computational Life Sciences|June 13, 2019
Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung CancerXinyong Zhang, Yuhua Wu, Jialin Lv, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|November 20, 2015
[Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma]Hui Zhang, Xinjie Yang, Na Qin, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|October 21, 2015
[Detection and Analysis of EGFR and KRAS Mutations
in the Patients with Lung Squamous Cell Carcinomas]Hui Zhang, Xinjie Yang, Na Qin, et al.Frontiers in Oncology|August 28, 2020
HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to PyrotinibXinyong Zhang, Jialin Lv, Yuhua Wu, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|January 22, 2021
[A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression]Hui Zhang, Xinjie Yang, Kun Li, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|February 26, 2020
[Clinical Value of Droplet Digital PCR and Super-ARMS Detection of Epidermal Growth Factor Receptor Gene Mutation in Plasma Circulating Tumor DNA of Patients with Advanced Lung Adenocarcinoma]Zhe Cao, Jing Wang, Na Qin, et al.Journal of Cancer Research and Clinical Oncology|May 26, 2018
Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotypeJing Xu, Xiaoting Zhao, Dengfeng He, et al.Scandinavian Journal of Immunology|March 29, 2019
Circulating CD137<sup>+</sup> CD8<sup>+</sup> T cells accumulate along with increased functional regulatory T cells and thoracic tumour burden in lung cancer patientsJingying Nong, Jinghui Wang, Xin Gao, et al.Plos One|July 4, 2014
Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCRJinghui Wang, Yiran Cai, Yujie Dong, et al.The Lancet. Oncology|April 20, 2012
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trialLi Zhang, Shenglin Ma, Xiangqun Song, et al.Pageof 14